BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 178 filers reported holding BLUEBIRD BIO INC in Q1 2022. The put-call ratio across all filers is 1.32 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $537,223 | +228.5% | 176,718 | +255.5% | 0.01% | +150.0% |
Q2 2023 | $163,526 | +15776.3% | 49,704 | -84.7% | 0.00% | -87.5% |
Q1 2023 | $1,030 | -62.4% | 324,001 | -18.2% | 0.02% | -70.4% |
Q4 2022 | $2,740 | -99.7% | 395,903 | +156.8% | 0.05% | +157.1% |
Q3 2022 | $976,000 | +34.1% | 154,178 | -12.3% | 0.02% | +10.5% |
Q2 2022 | $728,000 | -14.0% | 175,823 | +0.7% | 0.02% | -5.0% |
Q1 2022 | $847,000 | -77.7% | 174,649 | +46.8% | 0.02% | -72.2% |
Q2 2021 | $3,804,000 | -31.5% | 118,939 | -35.4% | 0.07% | -35.1% |
Q1 2021 | $5,551,000 | +112.2% | 184,100 | +204.6% | 0.11% | +50.0% |
Q4 2020 | $2,616,000 | +90.8% | 60,448 | +137.8% | 0.07% | +23.3% |
Q3 2020 | $1,371,000 | -23.3% | 25,417 | -13.2% | 0.06% | -32.6% |
Q2 2020 | $1,788,000 | +310.1% | 29,293 | +606.0% | 0.09% | +584.6% |
Q2 2017 | $436,000 | +42.5% | 4,149 | -8.0% | 0.01% | +85.7% |
Q3 2016 | $306,000 | -30.0% | 4,509 | -55.3% | 0.01% | -22.2% |
Q2 2016 | $437,000 | -72.8% | 10,098 | -59.6% | 0.01% | -80.0% |
Q4 2015 | $1,605,000 | -2.8% | 25,000 | +154.9% | 0.04% | -6.2% |
Q2 2015 | $1,651,000 | +124.0% | 9,806 | +60.7% | 0.05% | +100.0% |
Q1 2015 | $737,000 | -8.0% | 6,103 | -30.1% | 0.02% | -14.3% |
Q4 2014 | $801,000 | – | 8,736 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |